Skip to main content
. 2024 Feb 26;16(5):938. doi: 10.3390/cancers16050938

Figure 3.

Figure 3

PTEN loss is common in LMS. (A) With intact PTEN, the PI3K pathway is inhibited. With PTEN loss, the PI3K pathway is activated, resulting in downstream pathway activation. (B) Combined PI3K and mTOR inhibition was shown to result in compensatory ERK pathway activation, increasing cell proliferation. A possible combination to treat LMS is with dual PI3K/mTOR and ERK pathway inhibitors. Created with BioRender.com (accessed on 2 January 2024).